Notify me when Opaleye Management Inc. files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 54 | $752,786,283 | +$115,516,335 | -$113,568,233 | +$1,948,102 | HROW, LQDA, ETON, RYTM, APGE | 13F-HR | 17 Feb 2026, 16:05 |
| Q3 2025 | 43 | $707,320,956 | +$80,846,881 | -$57,913,318 | +$22,933,563 | HROW, ETON, LQDA, RYTM, IMNM | 13F-HR | 14 Nov 2025, 16:05 |
| Q2 2025 | 41 | $494,141,450 | +$57,149,524 | -$40,022,914 | +$17,126,610 | HROW, ETON, IMNM, SNWV, LQDA | Restatement | 15 Aug 2025, 11:00 |
| Q1 2025 | 45 | $449,152,370 | +$100,825,662 | -$142,415,135 | -$41,589,473 | HROW, ETON, SNWV, LQDA, RYTM | 13F-HR | 15 May 2025, 16:10 |
| Q4 2024 | 39 | $571,422,527 | +$40,063,958 | -$63,685,299 | -$23,621,341 | HROW, TGTX, CDXS, ETON, OCUL | 13F-HR | 14 Feb 2025, 16:05 |
| Q3 2024 | 44 | $599,558,377 | +$72,933,405 | -$66,912,606 | +$6,020,799 | HROW, TGTX, OCUL, ARVN, CDXS | 13F-HR | 14 Nov 2024, 16:05 |
| Q2 2024 | 51 | $437,656,642 | +$74,588,269 | -$59,238,789 | +$15,349,480 | HROW, TGTX, OCUL, RYTM, KROS | 13F-HR | 14 Aug 2024, 16:05 |
| Q1 2024 | 52 | $458,857,064 | +$77,084,080 | -$78,288,408 | -$1,204,328 | OCUL, HROW, TGTX, KROS, RYTM | Restatement | 29 May 2024, 16:05 |
| Q4 2023 | 47 | $373,240,349 | +$63,082,747 | -$56,351,944 | +$6,730,803 | HROW, TGTX, SLRN, RYTM, OCUL | 13F-HR | 14 Feb 2024, 16:05 |
| Q3 2023 | 41 | $304,940,292 | +$48,481,719 | -$88,284,504 | -$39,802,785 | HROW, SLRN, OCUL, TGTX, RYTM | 13F-HR | 14 Nov 2023, 20:04 |
| Q2 2023 | 47 | $414,519,284 | +$134,658,141 | -$34,595,392 | +$100,062,749 | SLRN, HROW, OCUL, TELA, CRNX | 13F-HR | 14 Aug 2023, 17:11 |
| Q1 2023 | 41 | $333,877,418 | +$42,132,643 | -$22,013,528 | +$20,119,115 | HROW, OCUL, TELA, RYTM, CRNX | 13F-HR | 12 May 2023, 18:49 |
| Q4 2022 | 40 | $287,572,164 | +$59,841,626 | -$44,914,436 | +$14,927,190 | HROW, TELA, RYTM, OCUL, CRNX | 13F-HR | 10 Feb 2023, 16:05 |
| Q3 2022 | 42 | $239,067,000 | +$30,251,227 | -$40,674,481 | -$10,423,254 | HROW, OCUL, RYTM, TELA, CRNX | 13F-HR | 14 Nov 2022, 16:20 |
| Q2 2022 | 47 | $221,854,000 | +$35,611,439 | -$57,269,350 | -$21,657,911 | HROW, OCUL, CDXS, CRNX, CYTK | 13F-HR | 15 Aug 2022, 16:03 |
| Q1 2022 | 45 | $321,998,000 | +$33,649,652 | -$60,414,026 | -$26,764,374 | OCUL, CDXS, CMRX, HROW, CRNX | 13F-HR | 16 May 2022, 16:05 |
| Q4 2021 | 39 | $471,486,000 | +$55,763,704 | -$74,417,777 | -$18,654,073 | CDXS, OCUL, CMRX, CLDX, HROW | 13F-HR | 14 Feb 2022, 16:05 |
| Q3 2021 | 48 | $535,390,000 | +$60,988,593 | -$46,916,441 | +$14,072,152 | OCUL, CLDX, CDXS, CMRX, HROW | 13F-HR | 15 Nov 2021, 19:17 |
| Q2 2021 | 48 | $572,750,000 | +$45,297,735 | -$94,574,210 | -$49,276,475 | OCUL, CMRX, CLDX, BBIO, CDXS | 13F-HR | 16 Aug 2021, 17:13 |
| Q1 2021 | 58 | $671,000,000 | +$146,771,519 | -$168,131,041 | -$21,359,522 | OCUL, CMRX, TARA, BBIO, CDXS | 13F-HR | 17 May 2021, 19:03 |
| Q4 2020 | 59 | $748,063,000 | +$83,960,534 | -$53,048,601 | +$30,911,933 | OCUL, TARA, EIDX, ETON, CDXS | 13F-HR | 12 Feb 2021, 17:15 |
| Q3 2020 | 55 | $488,907,000 | +$123,506,312 | -$71,867,092 | +$51,639,220 | OCUL, TARA, ETON, CRDF, AFIB | 13F-HR | 16 Nov 2020, 16:30 |
| Q2 2020 | 48 | $486,603,000 | +$183,256,555 | -$149,946,670 | +$33,309,885 | TARA, OCUL, NLTX, CCXI, ETON | 13F-HR | 14 Aug 2020, 16:47 |
| Q1 2020 | 43 | $377,310,000 | +$103,337,422 | -$178,481,141 | -$75,143,719 | TARA, FTSV, OCUL, APTOSE BIOSCIENCES INC, NLTX | 13F-HR | 15 May 2020, 16:30 |
| Q4 2019 | 47 | $509,651,000 | +$106,496,441 | -$31,660,617 | +$74,835,824 | EPZM, APTOSE BIOSCIENCES INC, CDXS, FTSV, STXS | 13F-HR | 14 Feb 2020, 16:30 |
| Q3 2019 | 49 | $276,541,000 | +$67,489,118 | -$60,665,635 | +$6,823,483 | CDXS, STXS, EPZM, IMMY, EIDX | 13F-HR | 14 Nov 2019, 16:30 |
| Q2 2019 | 43 | $328,094,000 | +$64,035,710 | -$111,838,040 | -$47,802,330 | CDXS, IMMY, AXGN, EPZM, QURE | 13F-HR | 14 Aug 2019, 16:30 |
| Q1 2019 | 53 | $361,134,000 | +$133,937,044 | -$107,257,391 | +$26,679,653 | CDXS, AXGN, EPZM, CERC, AMRN | 13F-HR | 15 May 2019, 16:30 |
| Q4 2018 | 47 | $267,617,000 | +$47,441,084 | -$77,603,605 | -$30,162,521 | CDXS, AXGN, LOXO, AMRN, BPMC | 13F-HR | 14 Feb 2019, 17:00 |
| Q3 2018 | 47 | $393,047,000 | +$44,959,836 | -$41,113,635 | +$3,846,201 | AXGN, CDXS, LOXO, AMRN, BPMC | 13F-HR | 14 Nov 2018, 16:30 |
| Q2 2018 | 36 | $382,531,000 | +$94,314,850 | -$90,219,512 | +$4,095,338 | AXGN, LOXO, CDXS, FGEN, BPMC | 13F-HR | 14 Aug 2018, 16:31 |
| Q1 2018 | 38 | $349,747,000 | +$70,254,632 | -$88,461,376 | -$18,206,744 | AXGN, BPMC, LOXO, CDXS, FGEN | 13F-HR | 14 May 2018, 17:00 |
| Q4 2017 | 35 | $312,298,000 | +$63,662,630 | -$63,896,697 | -$234,067 | AXGN, BPMC, FGEN, LOXO, IMMU | 13F-HR | 09 Feb 2018, 16:30 |
| Q3 2017 | 34 | $282,230,000 | +$36,775,046 | -$48,051,196 | -$11,276,150 | BPMC, AXGN, FGEN, IMMU, LOXO | 13F-HR | 14 Nov 2017, 16:17 |
| Q2 2017 | 41 | $239,398,000 | +$36,164,142 | -$30,643,295 | +$5,520,847 | BPMC, AXGN, FGEN, LOXO, SBBP | 13F-HR | 14 Aug 2017, 16:34 |
| Q1 2017 | 44 | $200,928,000 | +$40,719,965 | -$34,571,686 | +$6,148,279 | BPMC, AXGN, FGEN, NVLNF, CMRX | 13F-HR | 15 May 2017, 06:15 |
| Q4 2016 | 40 | $167,986,000 | +$44,464,509 | -$57,414,353 | -$12,949,844 | BPMC, AXGN, ARIA, GNMX, FGEN | 13F-HR | 21 Feb 2017, 16:27 |
| Q3 2016 | 44 | $191,082,000 | +$33,780,405 | -$35,974,564 | -$2,194,159 | BPMC, AXGN, ARIA, MDGN, AGIO | 13F-HR | 14 Nov 2016, 12:30 |
| Q2 2016 | 49 | $149,709,000 | +$30,649,641 | -$41,093,624 | -$10,443,983 | AXGN, MDGN, ARIA, FGEN, PROTALIX BIOTHERAPEUTICS INC | Restatement | 12 Aug 2016, 16:35 |
| Q1 2016 | 52 | $147,406,000 | +$32,727,687 | -$58,910,908 | -$26,183,221 | AXGN, ARIA, RARE, FGEN, MDGN | Restatement | 27 May 2016, 15:29 |
| Q4 2015 | 53 | $239,178,000 | +$50,036,769 | -$42,471,043 | +$7,565,726 | RARE, AXGN, FGEN, GERN, MDGN | 13F-HR | 12 Feb 2016, 12:57 |
| Q3 2015 | 49 | $203,221,000 | +$31,485,750 | -$49,548,442 | -$18,062,692 | CMRX, RARE, CEMP, AXGN, MDGN | 13F-HR | 13 Nov 2015, 10:44 |
| Q2 2015 | 46 | $242,983,000 | +$41,571,257 | -$38,191,939 | +$3,379,318 | CMRX, CEMP, RTRX, AMAG, ARIA | 13F-HR | 14 Aug 2015, 10:27 |
| Q1 2015 | 37 | $215,386,000 | +$50,081,325 | -$67,326,782 | -$17,245,457 | CMRX, CEMP, ARIA, RTRX, CLVSQ | 13F-HR | 15 May 2015, 11:41 |
| Q4 2014 | 36 | $197,898,000 | +$53,581,353 | -$21,324,971 | +$32,256,382 | CMRX, AGIO, CEMP, RTRX, ARIA | 13F-HR | 13 Feb 2015, 07:06 |
| Q3 2014 | 30 | $128,295,606 | +$25,728,933 | -$14,140,672 | +$11,588,261 | CMRX, PCYC, RTRX, ARIA, AGIO | 13F-HR | 14 Nov 2014, 10:27 |
| Q2 2014 | 27 | $115,981,000 | +$30,184,976 | -$35,046,239 | -$4,861,263 | CMRX, RTRX, ARIA, PCYC, GNMK | 13F-HR | 14 Aug 2014, 10:19 |
| Q1 2014 | 30 | $135,373,000 | +$63,466,998 | -$49,618,346 | +$13,848,652 | RTRX, ARIA, CMRX, PCYC, NSPR | 13F-HR | 15 May 2014, 10:48 |
| Q4 2013 | 23 | $127,387,015 | $0 | $0 | $0 | GENTY, GERN, PCYC, ARIA, P103PS | 13F-HR | 13 Feb 2014, 19:29 |